The ACC league office released its basketball matchups for next season and the year after Tuesday morning. The full list is here ( marvel at Virginias yet again favorable schedule). Below is a breakdown of what awaits Duke.
2014-15 home and away: UNC, Wake Forest, Syracuse, Notre Dame
Home: Miami, Georgia Tech, Clemson, Pittsburgh, Boston College
Road: Florida State, N.C. State, Virginia, Virginia Tech, Louisville
First impressions: The ACC obviously enjoyed Duke-Syracuse this past year, just as ESPN did (the two regular season games between the teams where the first and second-most watched college basketball broadcasts on the network last season). The league enjoyed the new rivalry so much that it scheduled another home-and-home series between the two schools. Duke-Syracuse is the only rotating home-and-home series that will be played twice in the first three years of the 15-team ACC. Syracuse wont be as intimidating without Tyler Ennis, Jerami Grant and C.J. Fair, but if this is a true rivalry game, the contests should be entertaining nonetheless.
When looking at Dukes home-only opponents for 2014-15, its a bit uninspiring. Just one (Pittsburgh) made the NCAA tournament, and the home-only opponents combine for a league-worst .422 conference winning percentage (Louisville wasnt factored into that calculation). Of course, UNC, the likely preseason favorite, will add a degree of difficulty to the home schedule, as will Syracuse.
Dukes road-only opponents were an even .500 (36-36) in ACC play last season, making it the leagues seventh-toughest road-only schedule. No surprise to see Duke make its initial conference trip to Louisville after not visiting Maryland last season.
2015-16 home and away: UNC, Wake Forest, N.C. State, Louisville
Home: Florida State, Virginia, Virginia Tech, Syracuse, Notre Dame
Road: Miami, Georgia Tech, Clemson, Pittsburgh, Boston College
This will be the schedule that awaits Luke Kennard and Sean Obi, who will both begin their Duke careers that season. Beyond that, hard to say much definitive.